Atai life sciences announces r&d day agenda

New york and berlin, oct. 20, 2022 (globe newswire) -- atai life sciences n.v. (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual r&d day. during this event, management and scientific leaders will provide a comprehensive review of atai's diversified mental health pipeline. the event will also provide updates on near-term catalysts, with a focus on the upcoming phase 2a topline results for pcn-101 (r-ketamine) for treatment-resistant depression (trd).
ATAI Ratings Summary
ATAI Quant Ranking